Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK138D1 +/- Ivonescimab in Advanced Breast Cancer
NCT07560124Phase 2Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of AK138D1 in breast cancer, sponsored by Akeso, Inc.. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
AK138D1
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07560124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07560124.